Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 10/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.40 |
| ▸ | KLK7 | P49862 | 2/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13811752 | 0.91 | HDAC8 (0.50) | HDAC8HDAC1ITGB3ITGA2BMEN1 | |
| SCHEMBL13811764 | 0.86 | HDAC8 (0.52) | HDAC8HDAC1ITGB3ITGA2BCXCR3 | |
| SCHEMBL13610590 | 0.85 | ITGB3 (0.40) | HDAC8HDAC1ITGB3ITGA2BCTSS | |
| SCHEMBL13811763 | 0.84 | HDAC1 (0.45) | HDAC8HDAC1ITGB3ITGA2BMEN1 | |
| SCHEMBL13811781 | 0.83 | HDAC8 (0.46) | HDAC8HDAC1ITGB3ITGA2BCTSS | |
| SCHEMBL16924987 | 0.83 | ITGB3 (0.52) | HDAC8HDAC1ITGB3ITGA2BMEN1 | |
| SCHEMBL5667917 | 0.80 | ITGB3 (0.57) | ITGB3ITGA2BKLK7KLK5 | |
| SCHEMBL11397295 | 0.80 | ITGB3 (0.52) | HDAC8HDAC1ITGB3ITGA2B | |
| SCHEMBL11397298 | 0.80 | ITGB3 (0.52) | HDAC8HDAC1ITGB3ITGA2B | |
| SCHEMBL10666091 | 0.80 | ITGB3 (0.47) | HDAC8HDAC1ITGB3ITGA2BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163705-A1 | CATIONIC LIPIDS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163705-A1 | CATIONIC LIPIDS | CETP, SGMS1, SGMS2 | HDAC8 1283/4885HDAC1 551/4885ITGB3 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.